IKNA Stock Overview
Operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Ikena Oncology, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.55 |
| 52 Week High | US$2.29 |
| 52 Week Low | US$1.22 |
| Beta | 0.49 |
| 1 Month Change | -9.36% |
| 3 Month Change | -8.82% |
| 1 Year Change | -31.42% |
| 3 Year Change | -89.15% |
| 5 Year Change | n/a |
| Change since IPO | -95.16% |
Recent News & Updates
Recent updates
Increases to CEO Compensation Might Be Put On Hold For Now at Ikena Oncology, Inc. (NASDAQ:IKNA)
Jun 01
Growth Investors: Industry Analysts Just Upgraded Their Ikena Oncology, Inc. (NASDAQ:IKNA) Revenue Forecasts By 31%
Nov 10Analysts Just Slashed Their Ikena Oncology, Inc. (NASDAQ:IKNA) EPS Numbers
Aug 15Need To Know: Analysts Are Much More Bullish On Ikena Oncology, Inc. (NASDAQ:IKNA) Revenues
May 20Will Ikena Oncology (NASDAQ:IKNA) Spend Its Cash Wisely?
Apr 29We Think Ikena Oncology (NASDAQ:IKNA) Needs To Drive Business Growth Carefully
Jan 06Companies Like Ikena Oncology (NASDAQ:IKNA) Are In A Position To Invest In Growth
Aug 06Party Time: Brokers Just Made Major Increases To Their Ikena Oncology, Inc. (NASDAQ:IKNA) Earnings Forecasts
Mar 23Ikena Oncology, Inc. (NASDAQ:IKNA) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Mar 21Is Ikena Oncology (NASDAQ:IKNA) In A Good Position To Deliver On Growth Plans?
Feb 19We're Not Very Worried About Ikena Oncology's (NASDAQ:IKNA) Cash Burn Rate
Nov 02Ikena Oncology (NASDAQ:IKNA) Is In A Good Position To Deliver On Growth Plans
Jul 13Shareholder Returns
| IKNA | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -3.7% | -0.3% | -2.7% |
| 1Y | -31.4% | 7.9% | 23.4% |
Return vs Industry: IKNA underperformed the US Pharmaceuticals industry which returned 7.9% over the past year.
Return vs Market: IKNA underperformed the US Market which returned 23.4% over the past year.
Price Volatility
| IKNA volatility | |
|---|---|
| IKNA Average Weekly Movement | 3.2% |
| Pharmaceuticals Industry Average Movement | 10.6% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: IKNA has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: IKNA's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 14 | Mark Manfredi | ikenaoncology.com |
Ikena Oncology, Inc. operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway. The company also develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex.
Ikena Oncology, Inc. Fundamentals Summary
| IKNA fundamental statistics | |
|---|---|
| Market cap | US$74.80m |
| Earnings (TTM) | -US$59.60m |
| Revenue (TTM) | US$659.00k |
113.5x
P/S Ratio-1.3x
P/E RatioIs IKNA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IKNA income statement (TTM) | |
|---|---|
| Revenue | US$659.00k |
| Cost of Revenue | US$40.57m |
| Gross Profit | -US$39.91m |
| Other Expenses | US$19.69m |
| Earnings | -US$59.60m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.24 |
| Gross Margin | -6,056.15% |
| Net Profit Margin | -9,043.85% |
| Debt/Equity Ratio | 0% |
How did IKNA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 08:44 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Ikena Oncology, Inc. is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Evan Seigerman | Credit Suisse |
| Judah Frommer | Credit Suisse |
| Robert Burns | H.C. Wainwright & Co. |